生血宁片辅助治疗妊娠期贫血的系统评价

目的 系统评价生血宁片辅助治疗妊娠期贫血的临床疗效和安全性。方法 检索中国学术期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、维普中文期刊全文数据库（VIP）、万方数据库、PubMed、Embase、Cochrane Library等数据库，时间为建库至2020年7月30日，筛选生血宁片辅助治疗妊娠期贫血的随机对照试验（RCTs）。采用RevMan 5.3软件对纳入的研究进行Meta分析，采用Cochrane系统工具评价文献质量。结果 共纳入10篇RCTs，1 208例患者。Meta分析结果示，生血宁片辅助治疗妊娠期贫血可以提高治疗总有效率[RR=1.20，95% CI=（1.14，1.26）]；红细胞水平[SMD=2.08，95% CI=（1.51，2.60）]、血红蛋白水平[SMD=1.91，95% CI=（1.51，2.31）]、转铁蛋白水平[SMD=2.12，95% CI=（1.95，2.29）]、血清铁水平[SMD=2.67，95% CI=（1.88，3.45）]均有一定的升高作用，同时可以减少不良反应的发生[RR=0.17，95% CI=（0.08，0.38）]，所有结果与对照组比较均有统计学意义（P<0.05）。结论 生血宁片辅助治疗妊娠期贫血可有效提高患者的总有效率，改善患者症状，提高患者红细胞、血红蛋白、转铁蛋白水平及血清铁水平，降低不良反应发生率。但纳入文献质量较低，存在一定发表偏倚，仍需要更多大样本、高质量的临床试验加以验证。

Systematic review of Shengxuening Tablet in adjuvant treatment of gestational anemia

Objective To evaluate the clinical efficacy and safety of Shengxuening Tablet in adjuvant treatment of gestational anemia. Methods Data was retrieved from CNKI, VIP, Wanfang, CBM, PubMed, Embase, Cochrane Library and other databases until the 30th July 2020. Screening a randomized controlled trial (RCT) of Shengxuening Tablet in the adjuvant treatment of anemia in pregnancy. Meta-analysis was conducted on the included studies using RevMan 5.3 software, and Cochrane systematic evaluation tool was used to evaluate literature publication bias. Results A total of 10 RCTs and 1 208 patients were included. Meta-analysis results showed that Shengxuening Tablet adjuvant treatment gestational anemia could improve the total effective rate[RR=1.20, 95%CI=(1.14, 1.26)]. It has a certain effect on the increase of red blood cell level[SMD=2.08, 95%CI=(1.51, 2.60)], hemoglobin level[SMD=1.91, 95%CI=(1.51, 2.31)], transferrin level[SMD=2.12, 95%CI=(1.95, 2.29)] and serum iron level[SMD=2.67, 95%CI=(1.88, 3.45)], and can reduce the incidence of adverse reactions in patients[RR=0.17, 95%CI=(0.08, 0.38)], all results were statistically significant (P<0.05). Conclusion Shengxuening Tablet in adjuvant treatment of pregnancy anemia can effectively improve the total effective rate and improve the symptoms of patients; increase the level of red blood cell, hemoglobin, transferrin and serum iron, and reduce the incidence of adverse reactions. However, the quality of the included literature is low, and there is a certain publication bias, which still needs to be verified by more large samples and high-quality experimental data.